Population Pharmacokinetics of Rezafungin in Patients with Fungal Infections

por Rubino, Christopher M., Flanagan, Shawn
Publicado 2021

1174. Phase 2 STRIVE Clinical Trial of Rezafungin for Treatment of Candidemia and/or Invasive Candidiasis Demonstrates Consistent Trough Concentrations Across Diverse Patient Popul...

por Flanagan, Shawn, Rubino, Christopher M, Sandison, Taylor
Publicado 2020

Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers

por Farr, Stephen J, Robinson, Cynthia Y, Rubino, Christopher M
Publicado 2015

Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data

por Lakota, Elizabeth A., Ong, Voon, Flanagan, Shawn, Rubino, Christopher M.
Publicado 2018

398 Pharmacokinetics of dalbavancin (DAL) in bone and associated tissues in patients undergoing orthopedic surgical procedures

por Baldassarre, James, Van Wart, Scott, Forrest, Alan, Rubino, Christopher, Dunne, Michael
Publicado 2014

Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methods

por Zhang, Li, Wicha, Wolfgang W, Bhavnani, Sujata M, Rubino, Christopher M
Publicado 2019

1417. Evaluating the Dissonance Between C(max) and AUC with Clinically Utilized Aminoglycoside (AG) Dosing Regimens: Use of Tobramycin (TOB) Against Pseudomonas aeruginosa (PA) as...

por Onufrak, Nikolas J, Bhavnani, Sujata M, Pogue, Jason M, Rubino, Christopher M
Publicado 2018

1105. Population Pharmacokinetic Analyses for Tebipenem After the Administration of Tebipenem Pivoxil Hydrobromide

por Ganesan, Harish, Kumar, Vipul, Bhavnani, Sujata M, Melnick, David, Rubino, Christopher M
Publicado 2021

A Pharmacokinetic Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Volunteers

por Pan, Lin, Belloni, Paula, Ding, Han Ting, Wang, Jianshuang, Rubino, Christopher M., Putnam, Wendy S.
Publicado 2017

Antibacterial Drug Development: A New Approach Is Needed for the Field to Survive and Thrive

por Safir, M. Courtney, Bhavnani, Sujata M., Slover, Christine M., Ambrose, Paul G., Rubino, Christopher M.
Publicado 2020

Model-Based Approach for Optimizing Ceftobiprole Dosage in Pediatric Patients

por Rubino, Christopher M., Cammarata, Anthony P., Smits, Anne, Schröpf, Sebastian, Polak, Mark, Litherland, Karine, Hamed, Kamal
Publicado 2021

2549. Pharmacometric Analyses to Support Sulbactam-Durlobactam (SUL-DUR) Dosing Regimens in Patients with Altered Renal Function

por Larson, Kajal, Bhavnani, Sujata M, Hammel, Jeffrey P, Cammarata, Anthony P, O’Donnell, John, Rubino, Christopher M
Publicado 2023

1408. Population Pharmacokinetic (PK) Model to Describe Epithelial Lining Fluid (ELF) Penetration of ASN-1 and ASN-2 after ASN100 Administration to Healthy Subjects

por Van Wart, Scott A, Stevens, Christopher, Magyarics, Zoltan, Luperchio, Steven A, Rubino, Christopher M, Ambrose, Paul G
Publicado 2018

Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis

por Chalmers, James D., Usansky, Helen, Rubino, Christopher M., Teper, Ariel, Fernandez, Carlos, Zou, Jun, Mange, Kevin C.
Publicado 2022

Pharmacokinetic-Pharmacodynamic Target Attainment Analysis to Support VL-2397 Dose Selection for a Phase 2 Trial in Patients with Invasive Aspergillosis

por Rubino, Christopher M, Smith, Larry R, Mammen, Mammen P, Hopkins, Andrew M, Lakota, Elizabeth A, Sullivan, Sean M
Publicado 2017

Time for Precision: A World Without Susceptibility Breakpoints

por Bader, Justin C, Lakota, Elizabeth A, Andes, David R, Rubino, Christopher M, Ambrose, Paul G, Bhavnani, Sujata M
Publicado 2018

Pharmacokinetics and Optimal Dose Selection of Cefazolin for Surgical Prophylaxis of Pediatric Patients

por Schmitz, Michael L., Rubino, Christopher M., Onufrak, Nikolas J., Martinez, Diana Valencia, Licursi, Diane, Karpf, Angela, Cetnarowski, Wes
Publicado 2020

1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida

por Lakota, Elizabeth A, Ganesan, Harish, Flanagan, Shawn, Ong, Voon, Sandison, Taylor, Bhavnani, Sujata M, Rubino, Christopher M, Ambrose, Paul G
Publicado 2018

1340. Population Pharmacokinetic (PK) Analysis of APX001 Using Phase 1 Data

por Trang, Michael, Bader, Justin C, Ople, Eric A, Kramer, William G, Hodges, Michael R, Bhavnani, Sujata M, Rubino, Christopher M
Publicado 2018

1561. Omadacycline Pharmacokinetics: Influence of Mortality Risk Score Among Patients with Community-Acquired Bacterial Pneumonia

por Lakota, Elizabeth A, Friedrich, Lawrence, Steenbergen, Judith N, McGovern, Paul C, Tzanis, Evan, Bhavnani, Sujata M, Rubino, Christopher M
Publicado 2019